Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | GNRHR | P30968 | 11/20 | 0.51 |
| ▸ | FPR1 | P21462 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | RXRG | P48443 | 2/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241202 | 0.87 | RXRA (0.56) | RXRACYP3A4RXRBRXRGCYP26A1 | |
| SCHEMBL6236296 | 0.86 | RXRA (0.55) | RXRACYP3A4GNRHRFPR1GPR183 | |
| SCHEMBL6889150 | 0.85 | RXRA (1.00) | RXRARXRBRXRGCYP26A1RARA | |
| SCHEMBL6238178 | 0.83 | RXRA (0.56) | RXRACYP3A4RXRBRXRGCYP26A1 | |
| SCHEMBL6240226 | 0.82 | RXRA (0.51) | RXRACYP3A4RXRBRXRGCYP26A1 | |
| SCHEMBL5834348 | 0.81 | GNRHR (0.68) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL3982018 | 0.81 | RXRA (0.72) | RXRACYP3A4RXRBRXRGCYP26A1 | |
| SCHEMBL6242867 | 0.81 | HNF4A (0.52) | RXRACYP3A4GNRHRRXRBRXRG | |
| SCHEMBL6237264 | 0.81 | RXRA (0.51) | RXRACYP3A4RXRBRXRGCYP26A1 | |
| SCHEMBL6245896 | 0.81 | RXRA (0.51) | RXRACYP3A4RXRBRXRGCYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207156-A1 | DIHYDROINDENE AND TETRAHYDRONAPHTHALENE COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-07-26 | — | — | US | disclosed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | RXRA 674/4885CYP3A4 3854/4885GNRHR 4711/4885 |
| US-20180207156-A1 | DIHYDROINDENE AND TETRAHYDRONAPHTHALENE COMPOUNDS | DHPS, DHODH, APP | RXRA 3174/4885CYP3A4 757/4885GNRHR 4461/4885 |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | RXRA 674/4885CYP3A4 3854/4885GNRHR 4711/4885 |
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885CYP3A4 1209/4885GNRHR 1102/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | RXRA 674/4885CYP3A4 3854/4885GNRHR 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.